Showing 771-780 of 2270 results for "".
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- Studies Evaluate the Reweighting of Parkinson Disease Assessment Tools for Improved Sensitivity and Efficiencyhttps://practicalneurology.com/news/studies-evaluate-the-reweighting-of-parkinson-disease-assessment-tools-for-improved-sensitivity-and-efficiency/2474181/Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and responsiveness in assessing motor and functional decline in people with Parkinson disease (PD), according to the results of 2 studies presented at
- Continuous, Subcutaneous Apomorphine Infusion Device Approved for Parkinson’shttps://practicalneurology.com/news/continuous-subcutaneous-apomorphine-infusion-device-approved-for-parkinsons/2473778/The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion dur
- National Institutes of Health Allege Research Misconduct by Prominent Neuroscientist and Investigator of α-Synuclein in PD and ADhttps://practicalneurology.com/news/nih-alleges-research-misconduct-by-prominent-neuroscientist-and-investigator-of-a-synuclein-in-pd-and-ad/2470601/Eliezer Masliah, MD, director of the National Institutes of Aging (NIA) neuroscience division, has been accused of research misconduct via the falsification, duplication, and manipulation of images, particularly western blot images. Much of Dr. Masliah’s work focuses on the role of &al
- New Drug Application Is Submitted for Vamorolone for Treating Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-drug-application-is-submitted-for-vamorolone-for-treating-duchenne-muscular-dystrophy/2470058/The submission of a new drug application (NDA) to the Food and Drug Administration (FDA) has been completed, seeking priority review for vamorolone (Santhera Pharmaceuticals, Prattein, Switzerland; and ReveraGen BioPharma, Rockville, MD) for the treatment of Duchenne muscular dystrophy (DMD).&nbs